Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9PPL

Structure of STING in complex with MK-2118

This is a non-PDB format compatible entry.
Summary for 9PPL
Entry DOI10.2210/pdb9ppl/pdb
DescriptorStimulator of interferon genes protein, (2S)-4-(5,6-dimethoxy-1-benzothiophen-2-yl)-2-methyl-4-oxobutanoic acid (3 entities in total)
Functional Keywordssting, mk-2118, immune system
Biological sourceHomo sapiens (human)
Total number of polymer chains1
Total formula weight21863.54
Authors
Lesburg, C.A.,Henderson, T.,Ho, T.,Hayes, R.P.,Bennett, J. (deposition date: 2025-07-21, release date: 2026-07-01, Last modification date: 2026-07-29)
Primary citationHenderson, T.,Altman, M.D.,Buevich, A.V.,Cash, B.,Cemerski, S.,Chang, W.,Chen, Y.,Childers, M.,Cumming, J.,Dandliker, P.J.,Feng, G.,Haidle, A.,Hayes, R.P.,Ho, T.,Jewell, J.P.,Kariv, I.,Knemeyer, I.,Kopinja, J.,Lacey, B.M.,Laskey, J.,Lesburg, C.A.,Liang, R.,Lim, J.,Long, B.J.,Lu, M.,Ma, Y.,Minnihan, E.C.,Otte, R.D.,O'Donnell, G.,Pan, B.S.,Perera, S.A.,Piesvaux, J.A.,Presland, J.P.,Price, L.,Rakhilina, L.,Sauvagnat, B.,Schroeder, G.K.,Sharma, S.,Trotter, B.W.,Tyagarajan, S.,Woo, H.,Wyss, D.F.,Xu, S.,Addona, G.H.,Bennett, D.J.
Discovery of MK-2118, a Small-Molecule Agonist of STING.
Acs Med.Chem.Lett., 17:1501-1507, 2026
Cited by
PubMed Abstract: Agonists of Stimulator of Interferon Genes (STING) have the potential to activate the innate and adaptive immune system for cancer treatment. Early efforts in identifying suitable therapeutics were focused on cyclic dinucleotide (CDN) analogs of 2',3'-cGAMP, the endogenous ligand to STING. CDNs lack of tractable bioavailability led us to consider small-molecule modulators of STING. We previously reported the identification of MSA-2, an orally available non-nucleotide STING agonist with antitumor activity. Optimization efforts in this series faced challenges with uniform activity across species, cell shift, and steep structure activity relationships. Herein we report lead optimization efforts guided by structure-based drug design to identify the MSA-2 analog MK-2118.
PubMed: 42445025
DOI: 10.1021/acsmedchemlett.5c00540
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.01 Å)
Structure validation

257179

PDB entries from 2026-07-29

PDB statisticsPDBj update infoContact PDBjnumon